The dimethyl fumarate is an oral drug, indicated in the treatment of the relapsing-remitting
multiple sclerosis (MS) , which efficacy and safety has been assessed and validated in two
randomised, placebo phase-controlled III international studies, organized by the
pharmaceutical company developing the molecule. TECFIDERA® (dimethyl-fumarate) has received
European approval on January 30, 2014, for the treatment of adult patients with relapsing
Treatment with dimethyl fumarate is introduced as part of the usual care under supervision of
a physician experienced in the treatment of the disease.
It has proved effective to reduce the number of relapses in patients with recurring-remitting
MS and reduce the number of patients who have relapses during treatment.
The objective of the study is to observe, in real conditions, on the one hand the tolerance
and the other evolution, clinical and radiologic disease in patients already treated by
dimethyl-fumarate and collect long-term safety data.